Contract development and manufacturing organization (CDMO), Stelis BioSource™, a division of Stelis Biopharma, has started the next phase of its continued investment program.
The latest phase will see the company, which offers end-to-end development and manufacturing services for biologics and biosimilars companies, start work on installing two 2,000L single-use bioreactor trains in its mammalian CGMP facility.
The bioreactor trains will be added to the company’s 200,000 sq ft state-of-the-art manufacturing facility which became fully operational earlier this year. The new manufacturing facility, which caters for drug product and drug substance manufacture, allows Stelis BioSource™ to offer fully integrated services from early phase development through to commercial manufacture and fill finish.
In addition to the drug substance and drug product capabilities, which cover process scale-up and CGMP manufacturing to commercial scales, the facility offers the latest analytical methodologies and equipment and operates under Stelis’ fully compliant quality management system.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
“Our CDMO facility in Bangalore is already fully operational working on both new and existing customer projects. The investment has been driven by both strong market demand and multiple opportunities to develop an offering for the delivery of affordable outsourced capabilities for biologics,” Dr. Roger Lias, CEO at Stelis Biopharma said. “At Stelis we’re committed to providing fully compliant, affordable biologics services to facilitate patient access to vital medications. Our experienced team and globally compliant facilities are capable of handling even the most complex projects. Our integrated offering means we can deliver robust and cost-effective processes and seamless manufacturing, allowing customer products to progress to market as efficiently as possible.”